Navigation Links
Cancer signatures uncovered
Date:8/15/2008

A new systematic analysis of the relationship between the neoplastic and developmental transcriptome provides an outline of trends in cancer gene expression. The research, published recently in BioMed Central's open access journal Genome Biology, describes how cancers can be divided into three groups distinguished by disparate developmental signatures.

Isaac S Kohane from Children's Hospital Boston and Harvard University, US, led a team of researchers who performed a comprehensive comparison of genes expressed in early developmental stages of various human tissues and those expressed in different cancers affecting these tissues. He says, "Our study reveals potentially clinically relevant differences in the gene expression of different cancer types and represents a reference framework for interpretation of smaller-scale functional studies".

One of the three described groups of cancers has an early developmental phenotype and expresses genes that are characteristic of stem cells. From a developmental perspective, this group presents very homogeneously. A second, more heterogeneous group tends to be more similar to late development and is characterized by an inflammatory signature. The third is a small group of cancers that present as a transition phenotype between these two extremes and displays both characteristics.

According to Kohane, "This segregation of tumors into three groups with distinct expression patterns is surprising. Clearly, the developmental trajectory provides a meaningful background for capturing large-scale differences in gene expression across diverse conditions".

The study's results will lead towards a better understanding of human disease from a 'macrobiological' approach to analyzing high-throughput data. According to the authors, "Shifting our focus from single sets of genes or processes to the biology of aggregates on the order of the entire transcriptome is likely to be useful in establishing highly robust molecular correlations between seemingly unrelated disease phenotypes".


'/>"/>
Contact: Graeme Baldwin
graeme.baldwin@biomedcentral.com
44-020-707-94804
BioMed Central
Source:Eurekalert

Related biology news :

1. Slipping through cell walls, nanotubes deliver high-potency punch to cancer tumors in mice
2. Scientists discover major genetic cause of colorectal cancer
3. Commercialization aim of grant supporting technology that destroys cancer cells
4. Experimental chemotherapy regimen shows promise in treating advanced lung cancer
5. Monash researchers uncover cancer survival secrets
6. Researchers find cancer-inhibiting compound under the sea
7. Pre-cancerous condition linked to chronic acid reflux faces several hurdles
8. Exposure to Agent Orange linked to prostate cancer in Vietnam veterans
9. Cold Spring Harbor Protocols highlights gene silencing, cancer cell biology methods
10. Plasma DNA level is a reliable marker of recurrent esophageal cancer, study finds
11. A new cellular pathway linked to cancer is identified by NYU researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
(Date:3/23/2016)... 23, 2016 ... Gesichts- und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler ... mit SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie ... die Möglichkeit angeboten, im Rahmen mobiler Apps ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... (NSO), which operates the highest sample volume laboratory in ... Tute Genomics and UNIConnect, leaders in clinical sequencing informatics ... the launch of a project to establish the informatics ... NSO has been contracted by the ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
(Date:6/23/2016)... -- Andrew D Zelenetz , ... Published recently in Oncology & ... Andrew D Zelenetz , discusses the fact ... placing an increasing burden on healthcare systems worldwide, ... the patents on many biologics expiring, interest in ...
Breaking Biology Technology: